Authors
Eren Veziroglu, Mahsa Gifani, Moozhan Nikpanah, Vrushab Gowda, Faraz Farhadi, Babak Saboury
Published in
Radiologic clinics of North America. Volume 64. Issue 6. Pages 1127-1144.
Abstract
Theranostics pairs molecular imaging with a therapeutic radiopharmaceutical directed at the same target, with PET assessing target expression, disease extent, interlesional heterogeneity, and FDG discordance. Three established applications are reviewed: PSMA PET-guided selection for lutetium-177-PSMA-617 in metastatic androgen pathway modulation-resistant prostate cancer, somatostatin receptor PET-guided peptide receptor radionuclide therapy in neuroendocrine tumors, and iodine-124/FDG PET within radioiodine therapy for differentiated thyroid cancer. Practical guidance covers patient selection, image interpretation, treatment planning, response assessment, and reporting. A key paradigm: diagnostic uptake confirms target availability but neither measures delivered dose nor guarantees response; biomarkers, dosimetry, and response frameworks remain variably validated.
PMID:
42957400
Bibliographic data and abstract were imported from PubMed on 30 Oct 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 9
- Comments 0